Semglee (insulin glargine-yfgn), an insulin glargine biosimilar developed by Indian company Biocon, has been listed as a preferred brand by one of the USA’s lar 21 October 2021
Court filings show that Canada-headquartered Bausch Health has agreed to pay $300 million to settle an antitrust suit related to diabetes med Glumetza (metformi 13 September 2021
Sumitomo Dainippon Pharma has launched Twymeeg (imeglimin hydrochloride) in Japan, the first launch of the diabetes drug anywhere in the world. 10 September 2021
British drugmaker AstraZeneca (LSE: AZN) has won approval in Japan for Forxiga (dapagliflozin), a SGLT2 blocker, for chronic kidney disease (CKD). 26 August 2021
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.